May 7, 2025
Danish Biotech Startup Ousia Pharma Secures Seed Funding from Omega Funds to Develop Pioneering Obesity Treatment
Copenhagen, Denmark —
Ousia Pharma, a biotech startup, has secured a substantial Seed funding round led exclusively by Omega Funds, as announced on May 6, 2025. Founded in 2022, the company is focused on developing novel pharmacotherapies for obesity and metabolic diseases using an innovative drug-targeting platform. The funding will support preclinical and early clinical development of its lead candidate: a dual-incretin-NMDA receptor antagonist conjugate aimed at achieving potent and sustained weight loss without compromising safety. Though the exact funding amount remains undisclosed, the investment marks a major milestone for the Danish company as it moves toward clinical validation.
About Ousia Pharma
Founded to revolutionize the treatment of obesity, Ousia Pharma's therapeutic approach targets the brain’s appetite control centers by delivering small-molecule neuroplasticity modulators via peptide-based hormone analogues. This platform is based on research initiated at the University of Copenhagen by Associate Professor Christoffer Clemmensen, one of the company’s co-founders alongside Anders B. Klein and Jonas Petersen. The technology aims to address challenges that limit current GLP-1-based obesity treatments, such as poor tolerability, variable weight loss response, and post-treatment weight regain.
Purpose of Financing
The new funding will accelerate development of Ousia’s peptide-drug conjugate pipeline. Specifically, the company plans to advance its dual-incretin-NMDA receptor conjugate into clinical trials, expand its proprietary delivery platform, and scale operations. These efforts are designed to meet the growing demand for next-generation obesity therapies with improved efficacy and safety profiles.
As part of the financing, several key industry leaders will join Ousia’s Board of Directors. These include Otello Stampacchia; Prof. Sir Mene Pangalos, former Executive Vice President of BioPharmaceuticals R&D at AstraZeneca; and Dr. Elisabeth Björk, previously SVP of Cardiovascular, Renal, and Metabolism R&D at AstraZeneca. Together with existing board members such as Ian Laquian and Christoffer Clemmensen, the expanded board strengthens Ousia’s leadership in clinical R&D and strategic execution.
CEO’s Insights
Anders B. Klein, PhD, CEO of Ousia Pharma, said:
“We are excited to enter the next phase of Ousia Pharma’s journey, advancing our groundbreaking platform towards clinical development” .“The strong support from Omega Funds enables us to accelerate the validation of our peptide-drug conjugate program, bringing us closer to a transformative treatment for obesity.”
Investors Perspective
Otello Stampacchia, Founder and Managing Director of Omega Funds, commented:
“Their novel dual-incretin-NMDA receptor antagonist conjugate represents a promising breakthrough in tackling several of the limitations of existing obesity treatments. We believe Ousia’s pioneering science and accomplished team position the company for meaningful impact and value creation.”
Prof. Sir Mene Pangalos, stated:
“Having worked in the pharmaceutical industry for decades, I can confidently say that the approach taken by Ousia Pharma is one of the most innovative I have encountered. I am extremely excited to contribute to bringing Ousia Pharma’s technology to patients.”
Conclusion
With a promising clinical roadmap, distinguished scientific leadership, and solid backing from Omega Funds, Ousia Pharma is positioned to become a key player in the fight against obesity and related metabolic conditions.
For updates, visit Ousia Pharma on LinkedIn.